Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)


Volume 20, 42 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Design

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 62nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
William A. Banks
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.288
5 - Year: 3.555

Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy

Author(s): Zachary Crees, Jennifer Girard, Zechary Rios, Gregory M. Botting, Kymberly Harrington, Caleb Shearrow, Luke Wojdyla, Amanda L. Stone, Srijayaprakash B. Uppada, Joseph T. Devito and Neelu Puri

Affiliation: University of Illinois College of Medicine at Rockford Department of Biomedical Sciences 1601 Parkview Avenue Rockford, Illinois 61107

Abstract

Cancer is a leading cause of death worldwide and an estimated 1 in 4 deaths in the United States is due to cancer. Despite recent advances in cancer treatment, adverse effects related to cancer therapy remain a limiting factor for many patients. The ideal cancer treatment would selectively target cancerous cells while sparing normal, healthy cells to offer maximal therapeutic benefit while minimizing toxicity. Telomeres are structurally unique DNA sequences at the end of human chromosomes, which play an integral role in the cellular mortality of normal cells. As telomeres shorten with successive cellular divisions, cells develop chromosomal instability and undergo either apoptosis or senescence. In many cancers, this apoptosis and senescence is avoided as normal telomere length is maintained by a ribonucleoprotein reverse transcriptase called telomerase. Telomerase is expressed in more than 85% of all cancers and confers cancerous cells with a replicative immortality, which is a hallmark of malignant tumors. In contrast, telomerase activity is not detectable in the majority of normal somatic cell populations. Therefore, the targeting of telomerase and telomere maintenance mechanisms represents a potentially promising therapeutic approach for various types of cancer. This review evaluates the roles of the GRN163L, T-oligo and small molecule G-quadruplex stabilizers as potential anticancer therapies by targeting telomerase and other telomere maintenance mechanisms

Keywords: Clinical trials, G-quadruplex, GRN163L, tankyrase, telomere, telomerase, telomerase inhibitor, T-oligo

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 20
First Page: 1
Last Page: 16
Page Count: 16
DOI: 10.2174/1381612820666140630100702
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science